


Participant Flow



Baseline Characteristics

Table 1 Baseline Demographic Characteristics and Menstrual Cycle Details

Characteristic	N	Mean	Min	Max
Age (years)	9	33.4	22	48
BMI (kg/m ²)	9	26.8	22	33
Menstrual Cycle Length (days)	9	29.2	24	35
Menses Duration (days)	9	4.0	3	5

Outcome Measures

Table 2 Clindamycin Concentration-Time Data after Administration of CHVI 100mg with a 24-hour Insertion Period

Time (hr)	CHVI 100mg			
	n	Mean (ng/mL)	SD (ng/mL)	CV (%)
0.00	9	0.00	0.00	NC
4.00	9	33.2	22.9	69.01
6.00	9	70.5	79.5	112.66
8.00	9	165	241	145.81
12.00	9	176	213	121.42
18.00	9	99.1	91.1	91.89
24.00	9	78.9	63.6	80.58
28.00	9	42.5	39.1	91.97
32.00	9	18.5	13.2	71.23
36.00	9	9.06	5.39	59.48
48.00	9	3.35	2.51	74.87
72.00	9	1.01	1.29	128.33
96.00	9	0.489	0.949	193.99
120.00	9	0.136	0.262	193.62

NC: Not Calculated

Table 3 Comfort Questionnaire Results

Timepoint	N	Unnoticeable		Noticeable, but tolerable	
		No. Subjects	%	No. Subjects	%
Immediate	9	6	67	3	33
6h	9	8	89	1	11
24h	9	6	67	3	33

Table 4 Vaginal pH Results

Visit	Timepoint	N	pH		
			Mean	Minimum	Maximum
Screen	-	9	4.90	4.4	5.3
Day 1	Pre-Dose	9	4.80	4.7	5.3
	12h	9	5.12	4.7	6.1
	24h	9	5.04	4.4	6.1

Table 5 Adverse Events

Adverse Event	Number of Subjects (n=9)	
	N	%
Catheter Site Related Reaction	1	11%
Pyrexia	1	11%
Gastroenteritis	1	11%
Asymptomatic Bacteriuria	1	11%
Vaginal Discharge	2	22%
Vaginal Infection	1	11%
Orthostatic Hypotension	1	11%
Thrombophlebitis	1	11%